ProGDerm Names J. Michael Delmage, Ph.D. as Chief Executive Officer


Boston (May 5, 2014) – ProGDerm, a biotechnology company that’s developing a natural approach to skin rejuvenation, today named J. Michael Delmage, Ph.D. as the new Chief Executive Officer.

With more than 25 years of experience in the pharmaceutical, biotechnology and medical-device industries, Delmage has served as a board member and key manager in the development of biotechnology products, therapeutic drugs, medical devices and over-the-counter (OTC) aesthetics. Delmage most recently served as President and CEO of Transvivo Inc., where in just two years he developed and obtained Federal Drug Administration and CE Mark Approvals for the Omni-DL system, a miniaturized portable dialysis system that supports all current acute dialysis treatments, apheresis and Continuous Renal Replacement Therapies.

Previously, he worked at Senetek PLC as Chief Technology Officer, overseeing development of the company’s aesthetics, medical devices and therapeutics, as well as Santen International, where he was one of three founding executives who built the 500-person pharmaceutical firm. He received his doctorate degree in cellular and molecular biology from the University of Southern California and a Master of Business Administration from Pepperdine University.

“Mr. Delmage offers a deep understanding of the science behind the technologies used to create sophisticated medical and biotechnology products, as well as extensive senior management experience overseeing fast-growing firms,” said Marc Eichenberger, Chief Operating Officer of Boston-based Allied Minds, the parent company of ProGDerm.

ProGDerm is utilizing a technology discovered at Lawrence Berkeley National Laboratory (LBNL) to create a natural, biologic approach to skin rejuvenation. The technology has potential applications in the aesthetics market for anti-aging products for appearance enhancement, which is expected to be more than $5 billion per year by 2015 in the US alone, and may also offer medical treatments for ailments ranging from wound healing and bed sores to hemifacial atrophy.

“ProGDerm offers the three elements that I look for in a company: A novel technology, an established need for it, and a business opportunity. I believe the opportunities for ProGDerm are significant, and I look forward to working with the Allied Minds team to develop and commercialize the ProGDerm technology in a timely and cost-effective manner,” Delmage said.

More information about ProGDerm can be found on the Allied Minds website at

About Allied Minds Inc.
Allied Minds is an innovative US science and technology development and commercialization company.  Our business model is to form, fund, manage and build products and businesses based on innovative technologies developed at leading US universities and federal research institutions. For more information, visit

Media Contact:
Christine Dunn
ArcPoint Strategic Communications
617.484.1660, x101

The Latest Press


Allied Minds’ Subsidiary Spin Transfer Technologies Produces Successful Prototype

Allied Minds’ Subsidiary Spin Transfer Technologies Produces Successful Prototype Boston, MA (4 February 2016) – Allied Minds (LSE: ALM), an innovativ..


Allied Minds’ Subsidiary Federated Wireless Raises $22 million

Allied Minds’ Subsidiary Federated Wireless Raises $22 million The fundraising values Federated Wireless at $82 million (including new invested capital), u..


HawkEye 360 Forms Advisory Board of Four Leading U.S. Security Experts

HawkEye 360 Forms Advisory Board of Four Leading U.S. Security Experts Boston, MA (January 21,2016) — HawkEye 360 Inc. today named four leading U.S. expe..

Privacy Policy Terms of Use